메뉴 건너뛰기




Volumn 1131, Issue , 2014, Pages 525-540

Fc engineering of antibodies and antibody derivatives by primary sequence alteration and their functional characterization

Author keywords

ADCC; Antibody engineering; CDC; Fc engineering; NK cell

Indexed keywords

ANTIBODY; CD20 ANTIBODY; FC RECEPTOR; HYBRID PROTEIN; MONOCLONAL ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

EID: 84934440590     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-992-5_33     Document Type: Article
Times cited : (1)

References (23)
  • 1
    • 28544449847 scopus 로고    scopus 로고
    • Divergent immunoglobulin g subclass activity through selective Fc receptor binding
    • Nimmerjahn F, Ravetch JV (2005) Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310(5753):1510-1512
    • (2005) Science , vol.310 , Issue.5753 , pp. 1510-1512
    • Nimmerjahn, F.1    Ravetch, J.V.2
  • 2
    • 42949157368 scopus 로고    scopus 로고
    • Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
    • Musolino A et al (2008) Immunoglobulin G fragment C receptor polymorphisms and clinical effi cacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26(11):1789-1796
    • (2008) J Clin Oncol , vol.26 , Issue.11 , pp. 1789-1796
    • Musolino, A.1
  • 3
    • 0642373290 scopus 로고    scopus 로고
    • Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
    • Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21(21):3940-3947
    • (2003) J Clin Oncol , vol.21 , Issue.21 , pp. 3940-3947
    • Weng, W.K.1    Levy, R.2
  • 4
    • 33646352962 scopus 로고    scopus 로고
    • Potent antibody therapeutics by design
    • Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6:343-357
    • (2006) Nat Rev Immunol , vol.6 , pp. 343-357
    • Carter, P.J.1
  • 5
    • 35748949531 scopus 로고    scopus 로고
    • Optimizing engagement of the immune system by anti-tumor antibodies: An engineer's perspective
    • Desjarlais JR et al (2007) Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov Today 12(21-22):898-910
    • (2007) Drug Discov Today , vol.12 , Issue.21-22 , pp. 898-910
    • Desjarlais, J.R.1
  • 6
    • 0028920695 scopus 로고
    • Recognition sites on human IgG for Fc gamma receptors: The role of glycosylation
    • Jefferis R, Lund J, Goodall M (1995) Recognition sites on human IgG for Fc gamma receptors: the role of glycosylation. Immunol Lett 44(2-3):111-117
    • (1995) Immunol Lett , vol.44 , Issue.2-3 , pp. 111-117
    • Jefferis, R.1    Lund, J.2    Goodall, M.3
  • 7
    • 0030470557 scopus 로고    scopus 로고
    • Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor i and influence the synthesis of its oligosaccharide chains
    • Lund J et al (1996) Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains. J Immunol 157(11): 4963-4969
    • (1996) J Immunol , vol.157 , Issue.11 , pp. 4963-4969
    • Lund, J.1
  • 8
    • 67649394336 scopus 로고    scopus 로고
    • Recombinant antibody therapeutics: The impact of glycosylation on mechanisms of action
    • Jefferis R (2009) Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol Sci 30(7): 356-362
    • (2009) Trends Pharmacol Sci , vol.30 , Issue.7 , pp. 356-362
    • Jefferis, R.1
  • 9
    • 0035794194 scopus 로고    scopus 로고
    • High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R
    • Shields RL et al (2001) High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276(9):6591-6604
    • (2001) J Biol Chem , vol.276 , Issue.9 , pp. 6591-6604
    • Shields, R.L.1
  • 10
    • 33645218704 scopus 로고    scopus 로고
    • Engineered antibody Fc variants with enhanced effector function
    • Lazar GA et al (2006) Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 103(11):4005-4010
    • (2006) Proc Natl Acad Sci U S A , vol.103 , Issue.11 , pp. 4005-4010
    • Lazar, G.A.1
  • 11
    • 0036670565 scopus 로고    scopus 로고
    • Engineering therapeutic antibodies for improved function
    • Presta LG et al (2002) Engineering therapeutic antibodies for improved function. Biochem Soc Trans 30(4):487-490
    • (2002) Biochem Soc Trans , vol.30 , Issue.4 , pp. 487-490
    • Presta, L.G.1
  • 12
    • 34548770705 scopus 로고    scopus 로고
    • Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors
    • Stavenhagen JB et al (2007) Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res 67(18): 8882-8890
    • (2007) Cancer Res , vol.67 , Issue.18 , pp. 8882-8890
    • Stavenhagen, J.B.1
  • 13
    • 58149510052 scopus 로고    scopus 로고
    • Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors
    • Sazinsky SL et al (2008) Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc Natl Acad Sci U S A 105(51):20167-20172
    • (2008) Proc Natl Acad Sci U S A , vol.105 , Issue.51 , pp. 20167-20172
    • Sazinsky, S.L.1
  • 14
    • 0035865063 scopus 로고    scopus 로고
    • Engineered antibodies with increased activity to recruit complement
    • Idusogie EE et al (2001) Engineered antibodies with increased activity to recruit complement. J Immunol 166(4):2571-2575
    • (2001) J Immunol , vol.166 , Issue.4 , pp. 2571-2575
    • Idusogie, E.E.1
  • 15
    • 80054839351 scopus 로고    scopus 로고
    • Combined Fc-proteinand Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC
    • Repp R et al (2011) Combined Fc-proteinand Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC. J Immunol Methods 373(1-2):67-78
    • (2011) J Immunol Methods , vol.373 , Issue.1-2 , pp. 67-78
    • Repp, R.1
  • 16
    • 0034717212 scopus 로고    scopus 로고
    • Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments
    • Boel E et al (2000) Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments. J Immunol Methods 239(1-2):153-166
    • (2000) J Immunol Methods , vol.239 , Issue.1-2 , pp. 153-166
    • Boel, E.1
  • 17
    • 84867835452 scopus 로고    scopus 로고
    • Fc engineering: Design, expression, and functional characterization of antibody variants with improved effector function
    • Derer S et al (2012) Fc engineering: design, expression, and functional characterization of antibody variants with improved effector function. Methods Mol Biol 907:519-536
    • (2012) Methods Mol Biol , vol.907 , pp. 519-536
    • Derer, S.1
  • 18
    • 0031014785 scopus 로고    scopus 로고
    • IgG effector mechanisms
    • Clark MR (1997) IgG effector mechanisms. Chem Immunol 65:88-110
    • (1997) Chem Immunol , vol.65 , pp. 88-110
    • Clark, M.R.1
  • 19
    • 79958262207 scopus 로고    scopus 로고
    • Molecular engineering to improve antibodies' anti-lymphoma activity
    • Peipp M, van de Winkel JG, Valerius T (2011) Molecular engineering to improve antibodies' anti-lymphoma activity. Best Pract Res Clin Haematol 24(2):217-229
    • (2011) Best Pract Res Clin Haematol , vol.24 , Issue.2 , pp. 217-229
    • Peipp, M.1    Van De Winkel, J.G.2    Valerius, T.3
  • 20
    • 76249100176 scopus 로고    scopus 로고
    • Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells
    • Jung ST et al (2010) Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells. Proc Natl Acad Sci U S A 107(2):604-609
    • (2010) Proc Natl Acad Sci U S A , vol.107 , Issue.2 , pp. 604-609
    • Jung, S.T.1
  • 21
    • 79955019213 scopus 로고    scopus 로고
    • Antibody-mediated coengagement of FcgammaRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus
    • Horton HM et al (2011) Antibody-mediated coengagement of FcgammaRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J Immunol 186(7):4223-4233
    • (2011) J Immunol , vol.186 , Issue.7 , pp. 4223-4233
    • Horton, H.M.1
  • 22
    • 53349120501 scopus 로고    scopus 로고
    • Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells
    • Richards JO et al (2008) Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther 7(8):2517-2527
    • (2008) Mol Cancer Ther , vol.7 , Issue.8 , pp. 2517-2527
    • Richards, J.O.1
  • 23
    • 77953659426 scopus 로고    scopus 로고
    • Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions
    • Moore GL et al (2010) Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs 2(2):181-189
    • (2010) MAbs , vol.2 , Issue.2 , pp. 181-189
    • Moore, G.L.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.